These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6159783)

  • 21. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The implications of procainamide metabolism to its induction of lupus.
    Uetrecht JP; Freeman RW; Woosley RL
    Arthritis Rheum; 1981 Aug; 24(8):994-1003. PubMed ID: 6169352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatic amines and the pathogenesis of lupus erythematosus.
    Reidenberg MM
    Am J Med; 1983 Dec; 75(6):1037-42. PubMed ID: 6196968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systemic lupus erythematosus-like syndrome induced by procainamide.
    Zeide MS; Wiesel S; Terry R; Stein D
    Clin Orthop Relat Res; 1978; (134):290-2. PubMed ID: 729256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term antiarrhythmic therapy with acetylprocainamide.
    Kluger J; Leech S; Reidenberg MM; Lloyd V; Drayer DE
    Am J Cardiol; 1981 Dec; 48(6):1124-32. PubMed ID: 6171156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The frequency of procainamide-induced systemic lupus erythematosus.
    Hope RR; Bates LA
    Med J Aust; 1972 Aug; 2(6):298-303. PubMed ID: 4117237
    [No Abstract]   [Full Text] [Related]  

  • 30. Antinuclear antibodies as indicators for the procainamide-induced systemic lupus erythematosus-like syndrome and its clinical presentations.
    Gorsulowsky DC; Bank PW; Goldberg AD; Lee TG; Heinzerling RH; Burnham TK
    J Am Acad Dermatol; 1985 Feb; 12(2 Pt 1):245-53. PubMed ID: 3882781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procainamide, acetylprocainamide, and drug-induced lupus erythematosus.
    Bernstein RE
    Lancet; 1979 Nov; 2(8151):1076. PubMed ID: 91813
    [No Abstract]   [Full Text] [Related]  

  • 32. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
    Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ
    Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy.
    Stec GP; Lertora JJ; Atkinson AJ; Nevin MJ; Kushner W; Jones C; Schmid FR; Askenazi J
    Ann Intern Med; 1979 May; 90(5):799-801. PubMed ID: 312047
    [No Abstract]   [Full Text] [Related]  

  • 35. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 36. Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study.
    Lessard E; Fortin A; Coquet A; Bélanger PM; Hamelin BA; Turgeon J
    J Chromatogr Sci; 1998 Jan; 36(1):49-54. PubMed ID: 9443381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose procainamide: low risk of complications with long-term use.
    van Pham C; Noguchi J; Quismorio FP; Haywood LJ
    J Natl Med Assoc; 1983 Jul; 75(7):705-8. PubMed ID: 6887275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Procainamide- and quinidine-induced immunological changes].
    Oka M; Räsänen J; Häkkinen P
    Duodecim; 1977; 93(3):206-12. PubMed ID: 300324
    [No Abstract]   [Full Text] [Related]  

  • 39. Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators.
    Kerin NZ; Meengs WL; Timmis GC; Salerno D; Haber HE; Singer RM
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):169-75. PubMed ID: 9140693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.